Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANL Adlai Nortye	$1.67 -1.4%	$1.55	$1.10 ▼ $3.89	$61.48M	-0.95	9,033 shs	1,136 shs
INMB INmune Bio	$2.41 +2.6%	$3.35	$1.89 ▼ $11.64	$64.06M	0.97	2.47 million shs	644,216 shs
LSB LakeShore Biopharma	$0.83 -0.8%	$0.95	$0.59 ▼ $8.60	$17.22M	0.56	73,146 shs	5,242 shs
OSTX OS Therapies	$2.48 +3.3%	$1.83	$1.12 ▼ $7.00	$79.09M	N/A	737,634 shs	1.08 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANL Adlai Nortye	0.00%	-1.42%	+15.69%	-9.95%	-44.28%
INMB INmune Bio	0.00%	-4.74%	-11.07%	-66.99%	-65.32%
LSB LakeShore Biopharma	0.00%	+6.28%	-27.91%	-22.60%	-81.37%
OSTX OS Therapies	0.00%	+20.39%	+37.78%	+47.62%	-40.24%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANL Adlai Nortye	1.7261 of 5 stars	3.0	3.0	3.3	0.0	0.0
INMB INmune Bio	1.9592 of 5 stars	3.3	2.0	1.4	1.7	0.6
LSB LakeShore Biopharma	0.6307 of 5 stars	0.0	5.0	0.0	0.8	0.6
OSTX OS Therapies	2.3842 of 5 stars	3.6	0.0	2.8	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANL Adlai Nortye	2.00	Hold	$9.00	440.22% Upside
INMB INmune Bio	2.57	Moderate Buy	$18.40	663.49% Upside
LSB LakeShore Biopharma	0.00	N/A	N/A	N/A
OSTX OS Therapies	3.25	Buy	$18.00	625.81% Upside

Current Analyst Ratings Breakdown

Latest LSB, OSTX, INMB, and ANL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/7/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
7/14/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
7/2/2025	INMB INmune Bio	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $8.00
7/1/2025	INMB INmune Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
7/1/2025	INMB INmune Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Outperform ➝ Sector Underperform
6/30/2025	INMB INmune Bio	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
6/30/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/24/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/9/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/2/2025	ANL Adlai Nortye	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANL Adlai Nortye	$5M	12.30	N/A	N/A	$0.69 per share	2.41
INMB INmune Bio	$10K	6,405.78	N/A	N/A	$1.45 per share	1.66
LSB LakeShore Biopharma	$85.67M	0.20	N/A	N/A	$3.35 per share	0.25
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANL Adlai Nortye	-$51.87M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	-$42.08M	-$2.48	N/A	N/A	N/A	N/A	-120.62%	-92.94%	10/30/2025 (Estimated)
LSB LakeShore Biopharma	-$13.93M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	-$7.79M	-$0.79	N/A	N/A	N/A	N/A	N/A	-569.57%	N/A

Latest LSB, OSTX, INMB, and ANL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	INMB INmune Bio	-$0.37	-$0.34	+$0.03	-$1.05	$0.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANL Adlai Nortye	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
LSB LakeShore Biopharma	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANL Adlai Nortye	0.02	1.41	1.41
INMB INmune Bio	N/A	4.20	4.20
LSB LakeShore Biopharma	0.05	1.02	0.75
OSTX OS Therapies	N/A	0.76	0.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANL Adlai Nortye	35.21%
INMB INmune Bio	12.72%
LSB LakeShore Biopharma	52.64%
OSTX OS Therapies	N/A

Insider Ownership

Company	Insider Ownership
ANL Adlai Nortye	N/A
INMB INmune Bio	35.70%
LSB LakeShore Biopharma	N/A
OSTX OS Therapies	13.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANL Adlai Nortye	127	36.90 million	N/A	Not Optionable
INMB INmune Bio	10	26.58 million	17.09 million	Optionable
LSB LakeShore Biopharma	773	20.77 million	N/A	N/A
OSTX OS Therapies	N/A	31.89 million	N/A	N/A

LSB, OSTX, INMB, and ANL Headlines

Recent News About These Companies

OS Therapies (NYSE:OSTX) Earns "Buy" Rating from D. Boral Capital

August 22 at 10:13 AM | marketbeat.com

OS Therapies Inc Reports Q2 2025 Earnings: Net Loss Per Share at $0.19, Revenue Details Unavailable

August 19, 2025 | gurufocus.com

OS Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update

August 19, 2025 | newsfilecorp.comN

Earnings Outlook For OS Therapies

August 18, 2025 | benzinga.com

OS Therapies Updates Quorum Rules for Shareholder Meetings

August 15, 2025 | tipranks.com

OS Therapies Delays Q2 2025 Financial Report

August 15, 2025 | tipranks.com

OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025

August 14, 2025 | newsfilecorp.comN

OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent ...

August 9, 2025 | finance.yahoo.com

OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

August 7, 2025 | newsfilecorp.comN

OS Therapies files to sell 3.76M shares of common stock for holders

August 6, 2025 | msn.com

OS Therapies Inc News (OSTX) - Investing.com

July 18, 2025 | investing.com

OS Therapies Inc. (NYSE-A: OSTX) Makes Important Strides in Rare Cancer Therapy

July 14, 2025 | theglobeandmail.com

OS Therapies Raises $4.2M Through Warrant Exercise

July 14, 2025 | tipranks.com

OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer

July 14, 2025 | newsfilecorp.comN

OS Therapies Inc.: Promising Cancer Immunotherapy and Strategic Regulatory Advancements Support Buy Rating

July 11, 2025 | tipranks.com

OS Therapies Provides Clinical & Global Regulatory Updates

July 10, 2025 | newsfilecorp.comN

Analysts Conflicted on These Healthcare Names: OS Therapies Incorporated (OSTX), Korro Bio (KRRO) and Veeva Systems (VEEV)

July 3, 2025 | theglobeandmail.com

OSTX - OS Therapies Inc Executives - Morningstar

July 3, 2025 | morningstar.comM

OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

July 3, 2025 | businesswire.com

Positive Buy Rating for OS Therapies Driven by Promising Phase 2b Trial Results and Regulatory Progress

July 2, 2025 | tipranks.com

OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor ...

June 30, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LSB, OSTX, INMB, and ANL Company Descriptions

Adlai Nortye NASDAQ:ANL

$1.67 -0.02 (-1.42%)

Closing price 08/22/2025 03:57 PM Eastern

Extended Trading

$1.65 -0.02 (-0.96%)

As of 08/22/2025 04:04 PM Eastern

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

INmune Bio NASDAQ:INMB

$2.41 +0.06 (+2.55%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.38 -0.04 (-1.45%)

As of 04:53 AM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

LakeShore Biopharma NASDAQ:LSB

$0.83 -0.01 (-0.84%)

Closing price 08/22/2025 03:58 PM Eastern

Extended Trading

$0.84 +0.01 (+0.72%)

As of 04:00 AM Eastern

LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.

OS Therapies NYSE:OSTX

$2.48 +0.08 (+3.33%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.53 +0.05 (+2.02%)

As of 04:46 AM Eastern

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time